High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease.
High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease.
复制标题
DOI：
10.3389/fphar.2016.00323
复制
发表时间：
2016
影响因子：
5.6
通讯作者：
Levine SJ
中科院分区：
文献类型：
--
作者：
Gordon EM;Figueroa DM;Barochia AV;Yao X;Levine SJ
载脂蛋白A-I（apoA-I）和高密度脂蛋白（HDL）介导胆固醇逆向转运出细胞。此外，HDL具有额外的保护功能，包括抗氧化、抗炎、抗凋亡和血管保护作用。相比之下，HDL在疾病或急性期反应的情况下可能变得功能失调，胆固醇释放和抗炎特性都降低。这些范例越来越多地被认为在肺系统中是活跃的，其中apoA-I和HDL在正常肺健康中以及在各种疾病状态中具有保护作用，所述疾病状态包括急性肺损伤（ALI）、哮喘、慢性阻塞性肺病、肺癌、肺动脉高压、肺纤维化和病毒性肺炎。然而，与心血管疾病中的观察结果相似，HDL可能变得功能失调，并导致呼吸系统疾病的发病机制。此外，合成的apoA-I模拟肽已显示在ALI、哮喘、肺动脉高压和流感肺炎的动物模型中具有保护作用。这些发现提供了证据支持apoA-I模拟肽可能被开发成一种新的治疗方法，可以预防或减轻肺部疾病的表现，如哮喘。因此，肺被定位为从心血管疾病剧本中学习一页，并利用HDL和apoA-I的保护特性作为一种新的治疗方法。
Apolipoprotein A-I (apoA-I) and high-density lipoproteins (HDL) mediate reverse cholesterol transport out of cells. Furthermore, HDL has additional protective functions, which include anti-oxidative, anti-inflammatory, anti-apoptotic, and vasoprotective effects. In contrast, HDL can become dysfunctional with a reduction in both cholesterol efflux and anti-inflammatory properties in the setting of disease or the acute phase response. These paradigms are increasingly being recognized to be active in the pulmonary system, where apoA-I and HDL have protective effects in normal lung health, as well as in a variety of disease states, including acute lung injury (ALI), asthma, chronic obstructive pulmonary disease, lung cancer, pulmonary arterial hypertension, pulmonary fibrosis, and viral pneumonia. Similar to observations in cardiovascular disease, however, HDL may become dysfunctional and contribute to disease pathogenesis in respiratory disorders. Furthermore, synthetic apoA-I mimetic peptides have been shown to have protective effects in animal models of ALI, asthma, pulmonary hypertension, and influenza pneumonia. These findings provide evidence to support the concept that apoA-I mimetic peptides might be developed into a new treatment that can either prevent or attenuate the manifestations of lung diseases, such as asthma. Thus, the lung is positioned to take a page from the cardiovascular disease playbook and utilize the protective properties of HDL and apoA-I as a novel therapeutic approach.
登录
查看更多内容
DOI：
10.1165/rcmb.2007-0020oc
发表时间：
2008-03-01
影响因子：
6.4
作者：
Bates, Sandra R.;Tao, Jian-Qin;Rothblat, George H.
通讯作者：
Rothblat, George H.
DOI：
10.1165/rcmb.2011-0322oc
发表时间：
2012-08-01
影响因子：
6.4
作者：
Dai, Cuilian;Yao, Xianglan;Levine, Stewart J.
通讯作者：
Levine, Stewart J.
影响因子：
7.1
作者：
Chandler, Paulette D.;Song, Yiqing;Wang, Lu
通讯作者：
Wang, Lu
DOI：
10.1152/ajplung.00077.2003
发表时间：
2003-10-01
影响因子：
4.9
作者：
Bortnick, AE;Favari, E;Bates, SR
通讯作者：
Bates, SR
影响因子：
3.8
作者：
Jiao, Yan-ling;Wu, Man-Ping
通讯作者：
Wu, Man-Ping